Selected research
Industry Research
Icodec Insulin Industry Research Report 2026
Market perspective
The global Icodec Insulin market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Icodec Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Icodec Insulin is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Icodec Insulin is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Icodec Insulin include Paijin Biotechnology, Sanofi, Lilly, Gan&Lee Pharmaceuticals and Novo Nordisk, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Icodec Insulin market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Icodec Insulin Market by Company
Paijin Biotechnology
Sanofi
Lilly
Gan&Lee Pharmaceuticals
Novo Nordisk
Icodec Insulin Segment by Type
Long-acting
Medium-acting
Icodec Insulin Segment by Application
Hospital
Clinic
Icodec Insulin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Icodec Insulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Icodec Insulin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Icodec Insulin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Icodec Insulin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Icodec Insulin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Icodec Insulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Long-acting
- Medium-acting
Applications
- Hospital
- Clinic
Companies covered
- Paijin Biotechnology
- Sanofi
- Lilly
- Gan&Lee Pharmaceuticals
- Novo Nordisk
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Icodec Insulin Market Size (2021-2032)
- 2.2.2 Global Icodec Insulin Sales (2021-2032)
- 2.2.3 Global Icodec Insulin Market Average Price (2021-2032)
- 2.3 Icodec Insulin by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Long-acting
- 2.3.3 Medium-acting
- 2.4 Icodec Insulin by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Icodec Insulin Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Icodec Insulin Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Icodec Insulin Revenue of Manufacturers (2021-2026)
- 3.4 Global Icodec Insulin Average Price by Manufacturers (2021-2026)
- 3.5 Global Icodec Insulin Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Icodec Insulin, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Icodec Insulin, Product Type & Application
- 3.8 Global Manufacturers of Icodec Insulin, Established Date
- 3.9 Global Icodec Insulin Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Paijin Biotechnology
- 4.1.1 Paijin Biotechnology Company Information
- 4.1.2 Paijin Biotechnology Business Overview
- 4.1.3 Paijin Biotechnology Icodec Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Paijin Biotechnology Icodec Insulin Product Portfolio
- 4.1.5 Paijin Biotechnology Recent Developments
- 4.2 Sanofi
- 4.2.1 Sanofi Company Information
- 4.2.2 Sanofi Business Overview
- 4.2.3 Sanofi Icodec Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi Icodec Insulin Product Portfolio
- 4.2.5 Sanofi Recent Developments
- 4.3 Lilly
- 4.3.1 Lilly Company Information
- 4.3.2 Lilly Business Overview
- 4.3.3 Lilly Icodec Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Lilly Icodec Insulin Product Portfolio
- 4.3.5 Lilly Recent Developments
- 4.4 Gan&Lee Pharmaceuticals
- 4.4.1 Gan&Lee Pharmaceuticals Company Information
- 4.4.2 Gan&Lee Pharmaceuticals Business Overview
- 4.4.3 Gan&Lee Pharmaceuticals Icodec Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Gan&Lee Pharmaceuticals Icodec Insulin Product Portfolio
- 4.4.5 Gan&Lee Pharmaceuticals Recent Developments
- 4.5 Novo Nordisk
- 4.5.1 Novo Nordisk Company Information
- 4.5.2 Novo Nordisk Business Overview
- 4.5.3 Novo Nordisk Icodec Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Novo Nordisk Icodec Insulin Product Portfolio
- 4.5.5 Novo Nordisk Recent Developments
5 Global Icodec Insulin Market Scenario by Region
- 5.1 Global Icodec Insulin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Icodec Insulin Sales by Region: 2021-2032
- 5.2.1 Global Icodec Insulin Sales by Region: 2021-2026
- 5.2.2 Global Icodec Insulin Sales by Region: 2027-2032
- 5.3 Global Icodec Insulin Revenue by Region: 2021-2032
- 5.3.1 Global Icodec Insulin Revenue by Region: 2021-2026
- 5.3.2 Global Icodec Insulin Revenue by Region: 2027-2032
- 5.4 North America Icodec Insulin Market Facts & Figures by Country
- 5.4.1 North America Icodec Insulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Icodec Insulin Sales by Country (2021-2032)
- 5.4.3 North America Icodec Insulin Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Icodec Insulin Market Facts & Figures by Country
- 5.5.1 Europe Icodec Insulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Icodec Insulin Sales by Country (2021-2032)
- 5.5.3 Europe Icodec Insulin Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Icodec Insulin Market Facts & Figures by Country
- 5.6.1 Asia Pacific Icodec Insulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Icodec Insulin Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Icodec Insulin Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Icodec Insulin Market Facts & Figures by Country
- 5.7.1 South America Icodec Insulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Icodec Insulin Sales by Country (2021-2032)
- 5.7.3 South America Icodec Insulin Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Icodec Insulin Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Icodec Insulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Icodec Insulin Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Icodec Insulin Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Icodec Insulin Sales by Type (2021-2032)
- 6.1.1 Global Icodec Insulin Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Icodec Insulin Sales Market Share by Type (2021-2032)
- 6.2 Global Icodec Insulin Revenue by Type (2021-2032)
- 6.2.1 Global Icodec Insulin Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Icodec Insulin Revenue Market Share by Type (2021-2032)
- 6.3 Global Icodec Insulin Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Icodec Insulin Sales by Application (2021-2032)
- 7.1.1 Global Icodec Insulin Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Icodec Insulin Sales Market Share by Application (2021-2032)
- 7.2 Global Icodec Insulin Revenue by Application (2021-2032)
- 7.2.1 Global Icodec Insulin Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Icodec Insulin Revenue Market Share by Application (2021-2032)
- 7.3 Global Icodec Insulin Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Icodec Insulin Value Chain Analysis
- 8.1.1 Icodec Insulin Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Icodec Insulin Production Mode & Process
- 8.2 Icodec Insulin Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Icodec Insulin Distributors
- 8.2.3 Icodec Insulin Customers
9 Global Icodec Insulin Analyzing Market Dynamics
- 9.1 Icodec Insulin Industry Trends
- 9.2 Icodec Insulin Industry Drivers
- 9.3 Icodec Insulin Industry Opportunities and Challenges
- 9.4 Icodec Insulin Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst